Pfizer Inc. (PFE) shares declined in premarket trading on Tuesday, slipping 1.7% to $25.62, as a new FDA label expansion for its hemophilia therapy Hympavzi failed to ignite investor enthusiasm. The market’s attention remained fixed on the company’s longer-term growth prospects, particularly in the obesity drug space, where recent mid-stage data for its monthly GLP-1 shot, berobenatide, highlighted tolerability concerns.
The FDA’s decision, announced Monday, expands Hympavzi’s indication to include patients 12 years and older with hemophilia A or B who have inhibitors, as well as children aged 6 to 11 with or without inhibitors. Pfizer highlighted that Hympavzi is now the first subcutaneous non-factor therapy approved for children 6 to 11 with hemophilia B, offering a once-weekly injection via an auto-injector pen as an alternative to frequent intravenous infusions.
“This approval could be a transformative option for patients 6 and up,” said Aamir Malik, Pfizer’s U.S. commercial chief, in a statement. Dr. Guy Young, director of the Hemostasis and Thrombosis Center at Children’s Hospital Los Angeles, noted that the shift to a once-weekly regimen could bring “a level of simplicity” that families have been seeking.
Despite the regulatory win, Hympavzi’s market impact is seen as limited for a $147 billion pharmaceutical giant. The bigger question remains Pfizer’s ability to compete in the lucrative obesity market, where it faces established players like Novo Nordisk (NVO) and Eli Lilly (LLY). On Saturday, Pfizer reported mid-stage results for berobenatide, a once-monthly GLP-1 receptor agonist acquired through its $10 billion purchase of Metsera. The VESPER-3 study showed a mean vomiting rate of approximately 23.3%, which fell within the 20-25% range that JPMorgan analyst Chris Schott had flagged as an investor threshold.
Pfizer executives are positioning berobenatide as a differentiated option due to its less frequent dosing and what Jim List, a Pfizer executive, described as a “smooth profile” thanks to the drug’s long half-life. However, the vomiting rate, combined with the absence of a near-term growth catalyst, has left investors cautious. The company is still awaiting late-stage data, regulatory filings, and evidence that monthly dosing can attract patients without new safety or tolerability issues.
In early trading, Eli Lilly edged up about 1.5%, while Novo Nordisk’s U.S.-listed shares fell 4.6%. The broader healthcare sector, as measured by the XLV ETF, slipped 0.2%, trailing the S&P 500 ETF (SPY), which posted a modest gain before the open.
Pfizer’s first-quarter 2026 results showed revenue of $14.5 billion, up 2% operationally, with adjusted earnings per share of $0.75. Excluding COVID-19 products Comirnaty and Paxlovid, revenue grew 7%. The company maintained its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted EPS of $2.80 to $3.00. Management noted that the forecast includes an approximately $1.5 billion headwind from declining COVID-19 product sales and another $1.5 billion hit from loss of exclusivity on certain brands. Planned R&D spending is set at $10.5 billion to $11.5 billion, supporting pipeline programs including those from the Metsera acquisition.
While Hympavzi strengthens Pfizer’s rare-disease portfolio, it does little to resolve the broader growth debate for a company of its size. The obesity opportunity with berobenatide remains a high-risk, high-reward bet that hinges on successful late-stage trials and commercial execution. Investors will be watching closely for further pipeline updates and any signs that the company can overcome tolerability hurdles to carve out a share of the rapidly expanding weight-loss market.
